CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Pathogen Panel Testing — Multiplex PCR-Based Panels (Outpatient)

Coverage and limits for multiplex molecular pathogen panel testing (gastrointestinal, respiratory, CNS, blood, urine, wound, and other panels) in outpatient settings for Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyPathogen Panel Testing — Multiplex PCR-Based Panels (Outpatient)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionOrder multiplex panels only when specific coverage criteria are met and document clinical findings (e.g., symptom duration, severity, CSF abnormalities) to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≤5 GIPsOutpatient GI panel (general)

≤11 GIPsOutpatient GI panel (immunosuppressed)

≤5 targetsOutpatient respiratory panel (meets criteria)

≥6 targetsLarge respiratory panels excluded

≥12 GIPsLarge GI panels excluded

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

CSF/blood/urine/woundCertain specimen panels excluded (outpatient)

Coverage Criteria for Multiplex Pathogen Panels

Covered indications

Covered when ALL of the following are met (by panel type and clinical scenario):

Outpatient GI panel (up to 5 targets): Multiplex PCR-based panel testing (up to 5 gastrointestinal pathogens) meets coverage criteria for individuals with either (a) community-acquired diarrhea of ≥7 days duration OR (b) diarrhea with signs or risk factors for severe disease (fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain, hospitalization and/or immunocompromised state).panel ≤5 GIPs

Outpatient setting

Outpatient GI panel (up to 11 targets) for immunosuppressed/HIV: Multiplex PCR-based panel testing (up to 11 gastrointestinal pathogens) meets coverage criteria for immunosuppressed or HIV positive patients who also have either (a) community-acquired diarrhea of ≥7 days duration OR (b) diarrhea with signs or risk factors for severe disease (fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain, hospitalization and/or immunocompromised state).panel ≤11 GIPs and patient immunosuppressed/HIV

Outpatient setting

Outpatient respiratory panel (up to 5 targets): Multiplex PCR-based panel testing (up to 5 respiratory pathogens) meets coverage criteria for individuals displaying signs and symptoms of a respiratory tract infection including at least one of: (a) temperature ≥102°F, (b) pronounced dyspnea, (c) tachypnea, or (d) tachycardia.panel ≤5 respiratory targets and ≥1 listed vital sign/feature

Outpatient setting

Not medically necessary / Not covered

Not covered in the outpatient setting:

Excluded panels: Multiplex PCR-based panel testing of 12 or more gastrointestinal pathogens; multiplex PCR-based panel testing of 6 or more respiratory pathogens; panel testing of pathogens in cerebrospinal fluid (CSF); molecular detection-based panel testing of pathogens in the blood; molecular detection-based panel testing of urine pathogens for UTI diagnosis; molecular-based panel testing for wound infections; molecular-based panel testing for general screening of microorganisms (e.g., MicroGenDX qPCR+ NGS).varies by item

Lists tests deemed not to meet coverage due to insufficient evidence

CSF/Meningitis-Encephalitis panel

Covered when ALL of the following are met

CNS panel clinical criteria: Patient has clinical presentation consistent with meningitis or encephalitis AND CSF findings (elevated leukocyte count or elevated protein or other supportive CSF abnormalities) indicating moderate-to-high pretest probabilitypretest probability = moderate-to-high

Ordering multiplex CSF panels in absence of supportive CSF findings increases false positives

Sepsis / Blood culture identification panels

Covered when ALL of the following are met

Sepsis/blood culture adjunct testing: Rapid molecular identification panels (e.g., BCID, T2Bacteria) used on positive blood culture bottles or directly on whole blood should be used to complement blood culture to provide faster organism identification and resistance markers when this will inform earlier targeted antimicrobial therapyused as adjunct to blood culture or when culture sensitivity is reduced (e.g., prior antibiotics)

Faster identification may improve outcomes; some assays identify limited target sets

Gastrointestinal pathogen panels

Covered when ALL of the following are met

Gastrointestinal panel: Multiplex GI panels may be used to rapidly identify enteric pathogens where results will alter clinical management (e.g., antibiotic decisions, infection control) and when conventional testing is insufficientn/a

Studies show higher detection rates and reduced antibiotic use and length of stay

UTI and Wound pathogen panels

Covered when ALL of the following are met

Urinary tract and wound panels: Commercial UTI and wound panels may be used when they provide actionable information beyond standard urine culture or wound culture and when results will change patient managementn/a

Panels detect many targets; some tests are not FDA-approved and have longer turnaround times

Coverage considerations and guideline-aligned criteria

Coverage and use considerations drawn from guideline positions and evidence summaries:

GI multiplex panels: Routine outpatient adoption of integrated GI multiplex PCR panels is not recommended due to insufficient evidence of clinical utility (NICE); consider coverage only when testing would change management or in high-risk/outbreak settings.

NICE: insufficient evidence; ACG: recommend FDA-approved culture-independent methods as adjuncts; IDSA: culture when isolation requested

Respiratory and critically ill patients: Multiplex respiratory viral panels are considered beneficial in immunocompromised, acutely ill adults who may be admitted, and critically ill (particularly ICU) patients; consider coverage when results will impact inpatient management.

American Society for Microbiology joint statement

CNS (FilmArray ME) panel: FilmArray ME panel shows high pooled sensitivity and specificity for many pathogens and may decrease antibiotic use and inpatient days; coverage may be appropriate in suspected meningitis/encephalitis where rapid identification would change therapy, recognizing lower sensitivity for certain organisms and reduced agreement for Cryptococcus antigen testing.

Clinical guidance and intended use

Guidance and intended-use statements informing coverage:

C. difficile testing approach: Use a stool toxin test as part of a multistep algorithm (GDH plus toxin; GDH plus toxin arbitrated by NAAT; or NAAT plus toxin) rather than NAAT alone when there are no preagreed institutional stool submission criteria

IDSA/SHEA weak recommendation, low quality evidence

Repeat testing for C. difficile within 7 days should not be performed7 days

IDSA/SHEA guidance

Respiratory panel use: Do not routinely order broad respiratory pathogen panels unless the result will affect patient management; rapid tests for RSV, influenza, or GAS are examples when immediate management may be affected

ASCP / ChoosingWisely

Outpatient multiplex PCR-based panel testing for large panels and certain specimen-specific panels is not covered. Specifically, multiplex gastrointestinal panels that include 12 or more GIPs, respiratory panels that include 6 or more respiratory pathogen targets, panels performed on cerebrospinal fluid (CSF), molecular detection–based panels performed on blood, molecular panels for urine pathogens for UTI diagnosis (for example, GENETWORx Molecular PCR UTI Test), molecular-based panel testing to diagnose or screen wound infections (for example, GENETWORx PCR Wound Testing), and molecular-based panel testing intended for general microorganism screening (for example, MicroGenDX qPCR+NGS) do not meet coverage criteria in the outpatient setting.

Molecular assays for encephalitis due to fungi, parasites, rickettsia, and spirochetes are not routinely available and require further investigation; current guidance emphasizes that CSF molecular testing should be performed when there is a moderate-to-high pretest probability of CNS infection based on clinical presentation and supporting CSF abnormalities (for example, elevated leukocyte count or protein) because false positives increase when tests are ordered without such findings.

Guidance from NICE indicates there is insufficient evidence to recommend routine adoption of integrated multiplex PCR tests for gastrointestinal pathogens (for example, xTAG GPP, FilmArray GI Panel) in routine practice; routine outpatient use should therefore be limited to circumstances where testing is expected to change management or in high-risk or outbreak settings.

The European Association of Urology (EAU) does not recommend molecular testing for uncomplicated urinary tract infections; instead the EAU recommends urine culture or dipstick testing for diagnosis, with antimicrobial susceptibility testing when indicated, and does not support routine use of broad molecular panels for uncomplicated UTI evaluation.

Within the cited reference material there are no additional explicit exclusion conditions beyond those already specified in the policy; this section of the source contains procedural code mappings and product references rather than new exclusion criteria.

The referenced portions of the document provide literature citations and vendor/product information and do not themselves state additional explicit coverage exclusions; they serve to support the policy's evidence base and list available assays and evaluations rather than introduce new exclusion conditions.

Large multiplex panels and certain specimen-based panels do not meet outpatient coverage criteria when there is insufficient published evidence demonstrating clinical benefit. Examples called out in the policy include commercially available large panels for gastrointestinal, respiratory, genitourinary, CSF, blood, and wound specimens; several proprietary assays and PLA-coded tests (such as Karius®, MicroGenDX, and large multiplex GI/respiratory panels listed with PLA/CPT codes) are enumerated in the policy but are specifically noted among tests that lack sufficient evidence to support routine outpatient coverage.

Ordering multiplex CSF PCR tests in patients without clinical signs or CSF laboratory abnormalities (that is, when pretest probability is low) increases the risk of false-positive results; molecular CSF testing should be reserved for patients with a clinical presentation and CSF findings consistent with meningitis or encephalitis, and results should be interpreted in the context of other diagnostic methods (for example, Gram stain, culture, serology) and prior antibiotic exposure.

Routine microbiological testing, including broad multiplex respiratory panels, is not recommended for outpatient adults with acute cough and suspected pneumonia unless the test result would change management; similarly, professional guidance cautions against routine ordering of broad respiratory pathogen panels unless the results are expected to affect patient care decisions.

Professional guidance (ASCP/Choosing Wisely) advises that broad respiratory pathogen panels should not be ordered routinely when results will not affect management; clinicians should document how the test result is expected to alter care when ordering wider panels.

The cited reference sections list procedure and PLA codes mapped to proprietary multiplex assays and other product information; these chunks do not themselves make explicit 'not medically necessary' determinations but provide the code-to-test mappings and vendor test names used elsewhere in the policy.

The reference lists and cited publications included in these sections support the policy's evidence synthesis but do not explicitly state additional 'not medically necessary' positions; they provide background literature, comparative evaluations, and product studies referenced by the coverage guidance.

Procedure and Proprietary Test Codes

Commercial panel products mentionedmixed

No codes listed

Listed multiplex laboratory CPT codes (GI, CNS, blood)CPT

87154	Culture, typing; identification of blood pathogen and resistance typing, when performed, by nucleic acid (DNA or RNA) probe, multiplexed amplified probe technique including multiplex reverse transcription, when performed, per culture or isolate, 6 or more targets.
87483	Infectious agent detection by nucleic acid (DNA or RNA); central nervous system pathogen (eg, Neisseria meningitidis, Streptococcus pneumoniae, Listeria, Haemophilus influenzae, E. coli, Streptococcus agalactiae, enterovirus, human parechovirus, herpes simplex virus type 1 and 2, human herpesvirus 6, cytomegalovirus, varicella zoster virus, Cryptococcus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87507	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

Respiratory multiplex CPT codesCPT

87631	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique.
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique.

PLA / Proprietary panel codesmixed

0068U	PLA: Candida species panel, amplified probe technique; proprietary MycoDART-PCR™ dual amplification real time PCR panel for 6 Candida species.
0086U	PLA: Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, with phenotypic MIC-based antimicrobial susceptibility (Accelerate PhenoTest™ BC kit).
0109U	PLA: Aspergillus species, real-time PCR for detection of DNA from 4 species, blood/lavage/tissue.
0112U	PLA: Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene (MicroGenDX qPCR & NGS).
0115U	PLA: Respiratory infectious agent detection by nucleic acid, 18 viral types and subtypes and 2 bacterial targets (ePlex RP Panel).
0140U	PLA: Fungal pathogen identification, DNA (15 fungal targets), blood culture (ePlex BCID Fungal Pathogens Panel).
0141U	PLA: Gram-positive organism identification and drug resistance element detection, DNA targets, blood culture (ePlex BCID Gram-Positive Panel).
0142U	PLA: Gram-negative bacterial identification and drug resistance element detection, DNA targets, blood culture (ePlex BCID Gram-Negative Panel).
0152U	PLA: DNA PCR and NGS, plasma, detection of >1,000 potential microbial organisms (Karius® Test).

Listed PLA/Codes - selectedCPT

0109U	Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species
0112U	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene

Listed PLA/Codes - GenMark, MicroGenDX, KariusCPT

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected
0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected
0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected
0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens

Respiratory pathogen panel codesCPT

0240U

Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (SARS-CoV-2, influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected

Listed PLA/Codes - respiratory, genitourinary, CSF, GI, wound panelsCPT

0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (SARS-CoV-2, influenza A, influenza B, RSV), upper respiratory specimen, each pathogen reported as detected or not detected
0321U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique
0323U	Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites, or fungi
0369U	Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique
0370U	Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab
0371U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative PCR, urine
0373U	Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen
0374U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine

inv-29: CSF volume for BioFire ME panel — 0.2 mL.

Required CSF volume for FilmArray ME panel0.2 mL of cerebrospinal fluid is used by the FDA‑cleared BioFire FilmArray Meningitis/Encephalitis (ME) panel to test ~14 pathogens in one hour.

Purpose of specimen volume noteIndicates the minimal CSF input reported by the manufacturer for the ME panel; relevant when ordering CSF multiplex testing and for sample adequacy assessment.

Specimen typeCerebrospinal fluid (CSF) obtained via lumbar puncture is the intended specimen for the FilmArray ME panel.

inv-30: Repeat testing interval (C. difficile) — do not repeat within 7 days.

Provider Actions, Documentation, and Authorization

Prior Authorization

Benefit-dependent coverage and limits

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the 'Applicable State and Federal Regulations' section of this policy document. Outpatient multiplex PCR panel coverage and limits vary by anatomic source and panel size: limited-size GI and respiratory panels may meet coverage for specific clinical scenarios, whereas large multiplex panels and certain specimen types are not covered.

Outpatient GI panels: up to 5 GIPs may meet coverage for community-acquired diarrhea ≥7 days or diarrhea with severe features (fever, bloody diarrhea/dysentery, dehydration, severe abdominal pain, hospitalization, immunocompromised state).
Outpatient GI panels for immunosuppressed/HIV+ patients: up to 11 GIPs may meet coverage with same clinical indications.
Outpatient respiratory panels: up to 5 respiratory pathogens may meet coverage when patient has respiratory infection signs and at least one: temperature ≥102°F, pronounced dyspnea, tachypnea, or tachycardia.
Do not order outpatient multiplex PCR testing of 12 or more GI pathogens (does NOT meet coverage).
Do not order outpatient multiplex PCR testing of 6 or more respiratory pathogens (does NOT meet coverage).
Outpatient multiplex PCR testing of CSF, blood, urine for UTIs, wound infections, and general screening (e.g., broad NGS/qPCR assays) does NOT meet coverage in the outpatient setting due to insufficient evidence or unclear clinical benefit.

Background and Context

Multiplex PCR–based assays detect multiple pathogens simultaneously and are generally more sensitive and faster than many conventional methods; for CNS testing, meta-analysis data demonstrate high pooled sensitivities and specificities for the FilmArray Meningitis/Encephalitis panel overall, though sensitivity is lower for selected organisms (for example, Listeria monocytogenes and HSV-1) and certainty of evidence is considered low.

Key Definitions and Terms

inv-58: GIPs — Gastrointestinal pathogens

DefinitionGIPs = Gastrointestinal pathogens; term used to indicate enteric bacteria, viruses, and parasites tested in panels.

Context of useReferenced in coverage criteria distinguishing allowable outpatient GI panels by number of GIPs (eg, ≤5 or ≤11 targets depending on clinical scenario).

SpecimenGastrointestinal pathogen panels are performed on stool specimens (eg, preserved in Cary‑Blair transport media) from symptomatic patients.

inv-59: RPP / RP

DefinitionRPP / RP = Respiratory pathogen panel; multiplex assays that detect multiple viral and bacterial respiratory pathogens.

Intended patientsIntended for symptomatic patients with signs of a respiratory infection; FDA‑cleared respiratory panels detect multiple respiratory virus nucleic acids from nasopharyngeal specimens.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyPathogen Panel Testing — Multiplex PCR-Based Panels (Outpatient)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionOrder multiplex panels only when specific coverage criteria are met and document clinical findings (e.g., symptom duration, severity, CSF abnormalities) to support medical necessity.

SourceLink

On This Page

Evidence: pooled sensitivity/specificity and PPA values; clinical impact on antibiotic days

Blood culture identification panels: Multiplex panels from positive blood cultures can identify organisms and resistance genes earlier than conventional methods and are associated with more judicious antibiotic use; coverage appropriate as adjunct to conventional culture and susceptibility testing.

Studies show earlier results and improved stewardship

C. difficile testing: Do not perform NAAT alone for all stool specimens when institutional stool submission criteria are not preagreed; use multistep algorithms (GDH + toxin +/- NAAT) and do not repeat testing within 7 days; interpret positive molecular results with clinical correlation due to possible asymptomatic colonization.

IDSA/SHEA and CDC guidance

FDA intended use for multiplex panels:

FDA-cleared multiplex respiratory, GI, blood culture, meningitis, and other panels are intended for use on symptomatic patients with signs and symptoms of the corresponding infection

Multiple FDA approvals cited

Repeat testing interval for C. difficile

Do not repeat C. difficile testing within 7 days (repeat testing within 7 days should not be performed).

Recommended testing approachUse a multistep algorithm (GDH + toxin; GDH + toxin arbitrated by NAAT; or NAAT + toxin) rather than NAAT alone when institutional stool submission criteria are not preagreed.

Interpretation cautionMolecular detection can identify colonization; interpret positive results with clinical correlation to avoid misdiagnosis.

inv-31: Number of targets reported — Varies by panel

Examples — small respiratory panelsCPT 0240U: respiratory panel reporting 3 targets (SARS‑CoV‑2, influenza A, influenza B).

Examples — expanded respiratory panelCPT 0241U: respiratory panel reporting 4 targets (SARS‑CoV‑2, influenza A, influenza B, RSV).

Examples — large multiplex panels with organism and resistance targetsPLA/CPT examples include 0369U (GI panel: 31 organism targets + up to 21 resistance genes), 0370U (wound panel: 34 organisms + up to 21 resistance genes), and 0373U (respiratory: 17 bacteria, 8 fungi, 13 viruses + 16 resistance genes).

Prior Authorization

CSF molecular panel prior authorization consideration

Molecular CSF panels should be ordered only when the clinical presentation and CSF laboratory findings indicate a moderate-to-high pretest probability of CNS infection. Use CSF cell count, glucose, and protein as screening tests prior to molecular testing. Ordering multiplex CSF panels in the absence of supportive CSF findings (for example, normal leukocyte count and protein) increases the risk of false positives and reduces predictive value.

Reserve CSF multiplex testing for suspected viral encephalitis (especially Herpesviridae) or when bacterial meningitis is suspected but standard culture/Gram stain may be compromised (e.g., after prior antibiotics).
Recognize that for many non–Herpesviridae viral encephalitides, a negative multiplex PCR does not exclude infection; consider serology and other methods when clinically indicated.
Document CSF findings (cell count, glucose, protein) and clinical signs/symptoms to support testing.
Clinical sensitivity/predictive value for many targets is uncertain; interpret results in clinical context.

Documentation Required

Prior authorization - code listing

Some proprietary and multiplex molecular infectious-disease assays are mapped to specific CPT/PLA/U codes. Verify payer prior authorization requirements before ordering these proprietary/PLA-coded tests; include the specific test name and performing laboratory on the claim or prior authorization request.

Examples of applicable procedure codes and proprietary tests (not exhaustive): 87154, 87483, 87505–87507, 87633, 87636, 87637.
Selected PLA/U codes and associated proprietary tests: 0068U (Candida species panel — MycoDART-PCR), 0086U (Accelerate PhenoTest BC), 0109U (Aspergillus PCR panel), 0112U (MicroGenDX qPCR & NGS), 0115U (ePlex RP Panel), 0140U/0141U/0142U (ePlex BCID panels), 0152U (Karius® Test), 0240U/0241U (Cepheid Xpert CoV-2/Flu/RSV), 0321U (Bridge UTI Detection), 0323U (Johns Hopkins mNGS CSF), 0369U–0374U (large multiplex/NGS panels).

Note

References and vendor product information — no PA stated

This section cites clinical guidelines, peer-reviewed literature, and vendor product pages to support clinical-context recommendations. It does not itself specify an explicit prior authorization (PA) exemption for listed vendors/tests — check payer-specific PA rules.

Vendor and product information cited includes Luminex NxTAG and xTAG GPP, BioFire FilmArray meningitis/encephalitis panel, QIAGEN QIAstat-Dx, Luminex product pages, Karius, T2Biosystems, Cepheid Xpert, T2Bacteria, and others.
Clinical guideline citations: IDSA/SHEA C. difficile guidance, ACG C. difficile recommendations, ASCP ChoosingWisely statements, NICE guidance on GI multiplex panels, and Surviving Sepsis Campaign references.

Denial Risk

Denial triggers

Ordering disallowed or non-covered panel sizes/specimen types, repeat testing contrary to guideline recommendations, or testing without documentation of clinical indication may trigger claim denial.

Outpatient GI panels of 12+ targets and outpatient respiratory panels of 6+ targets are denial triggers.
Repeat C. difficile testing within 7 days or testing asymptomatic patients (stool testing without diarrhea) may be denied per IDSA/SHEA and ACG guidance.
Ordering CSF multiplex testing without supportive CSF laboratory evidence (elevated leukocyte count or protein) may lead to denial or clinical review due to increased false positives.

Documentation Required

Pretest probability and CSF screening

Ensure pretest probability is documented and CSF laboratory screening (cell count, glucose, protein) supports the decision to test. For CNS testing, only patients with moderate-to-high pretest probability based on clinical presentation and CSF findings should undergo multiplex molecular testing to reduce false positives.

Document neurologic signs/symptoms (e.g., altered mental status, focal deficits, fever), duration, and risk factors.
Document CSF indices: leukocyte count, differential, glucose, protein to support testing.
If CSF findings are not supportive, consider alternative diagnostic pathways (culture, targeted PCRs, serology).

Documentation Required

Interpretation of negative results

A negative result from a multiplex PCR panel, particularly for non–Herpesviridae causes of encephalitis, does not reliably exclude infection. Use combined diagnostic methods (serology, targeted PCRs, culture) and clinical correlation when ruling out CNS infections.

For suspected encephalitis other than Herpesviridae, do not rely solely on a single negative multiplex panel result to exclude disease.
When clinical suspicion remains high despite a negative panel, pursue additional diagnostics (e.g., serology, repeat testing, targeted assays).

Note

Misinterpretation of multiplex results

Multiplex molecular assays can detect colonization or asymptomatic carriage (for example, C. difficile) and may identify organisms of uncertain clinical relevance. Results must be interpreted in the context of clinical presentation and pretest probability to avoid inappropriate treatment.

CDC notes molecular assays can be positive in asymptomatic individuals; exercise caution when interpreting multiplex results for C. difficile.
ASCP/ChoosingWisely advises against routine broad respiratory panels unless the result will affect management.
Avoid using NAAT alone for C. difficile without a multistep algorithm (GDH/toxin ± NAAT) where appropriate.

Note

Not stated in these chunks — denial triggers

Some sections of the source literature and vendor listings do not state explicit denial triggers or authorization requirements; they serve as background references rather than definitive PA rules. Nonetheless, absence of stated PA does not imply coverage — verify payer-specific PA policies.

References and vendor product pages may lack PA statements — treat them as informational.
Check Blue Cross Blue Shield of Tennessee policy and PA resources for current submission requirements.

Documentation Required

Procedure code documentation

Procedure code documentation should include the specific test performed (proprietary panel name when applicable), the performing laboratory, specimen source, and clinical indication. Include supporting clinical documentation (symptoms, duration, CSF indices, immunosuppression status) with prior authorization requests or claims to minimize denial risk.

On claims or PA requests, list the exact CPT/PLA code and proprietary test name (if known).
Attach or reference clinical notes documenting the indication, duration of symptoms, vital signs, and relevant lab results (e.g., CSF cell count/protein or stool toxin/GDH results).
For C. difficile testing, document adherence to multistep testing algorithms per IDSA/SHEA when applicable.

Note

No provider documentation or submission requirements specified

This section lists mappings of proprietary tests to CPT and PLA codes and cites product/vendor webpages and guideline references; it does not specify additional provider submission formats beyond standard PA/claim requirements. Providers should follow payer submission instructions for PA or claims.

No special provider documentation form is specified here — include standard clinical documentation and test details with PA/claims.
Procedure codes in this policy are for reference and may not be all-inclusive; confirm codes with the performing laboratory and payer.
When ordering proprietary panels, record the vendor/test name and lab to align with listed PLA codes.

Note

References and vendor/product webpages for multiplex PCR and syndromic panels

Selected references and vendor/product webpages that inform the policy and may be useful to ordering clinicians and reviewers are listed; these do not replace payer policy or PA requirements.

Luminex NxTAG and xTAG GPP product pages (Luminex, 2023a/b).
BioFire FilmArray meningitis/encephalitis panel (BioFire, 2023c).
QIAGEN QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAGEN, 2023).
Karius®, T2Biosystems, Cepheid Xpert product pages.
Guideline citations: NICE (2017), IDSA/SHEA (McDonald et al., 2018), ACG (Surawicz et al., 2013), ASCP ChoosingWisely (2019).

Documentation Required

Pretest clinical requirements

Prior to ordering multiplex PCR panels, perform a clinical evaluation documenting symptom duration, severity features, immunosuppression status, and pertinent laboratory/CSF findings. For C. difficile testing, follow stool submission criteria and multistep algorithms where applicable.

Document duration of symptoms (e.g., diarrhea ≥7 days for outpatient GI panels).
Record severe features (fever, bloody diarrhea, dehydration, severe abdominal pain, hospitalization) or immunocompromised status.
For respiratory panels, document signs such as temperature ≥102°F, pronounced dyspnea, tachypnea, or tachycardia.
For CSF testing, document CSF indices (cell count, protein, glucose) and neurologic exam findings prior to molecular testing.
For C. difficile, test only stools from patients with diarrhea and follow GDH/toxin ± NAAT multistep algorithms; avoid repeat testing within 7 days.

Billing Rule

C. difficile testing pathway

Follow guideline-recommended C. difficile testing pathways: test only diarrheal stool, prefer multistep algorithms (GDH + toxin ± NAAT or NAAT + toxin) over NAAT alone when there are no preagreed stool submission criteria, discourage repeat testing, and do not test for cure.

Only test stools from patients with diarrhea. (ACG strong recommendation)
Use multistep testing algorithms for C. difficile (GDH/toxin ± NAAT) rather than NAAT alone where appropriate (IDSA/SHEA recommendation).
Do not repeat C. difficile testing within 7 days; do not test for cure.
Recognize that molecular assays may detect asymptomatic carriage; correlate results with clinical presentation.

Coverage notePolicy limits outpatient respiratory panel coverage by number of targets (eg, panels with ≥6 respiratory targets are not covered in outpatient setting).

inv-60: CSF — Cerebrospinal fluid

DefinitionCSF = Cerebrospinal fluid; specimen source for CNS panels (eg, meningitis/encephalitis panel) obtained via lumbar puncture.

Coverage stanceMultiplex CSF panels are not covered in the outpatient setting per the policy exclusions; CSF molecular testing is reserved for patients with clinical signs/suspicion of CNS infection.

Diagnostic roleCSF molecular testing may be used when viral encephalitis (eg, Herpesviridae) is suspected; a negative multiplex PCR does not exclude non‑Herpesviridae infections and requires additional testing/clinical correlation.

inv-61: Multiplex PCR panel

DefinitionMultiplex PCR panel = A molecular assay that simultaneously detects multiple bacterial, viral, fungal, or parasitic pathogen targets (and sometimes resistance genes) from a single specimen.

Use casesUsed to rapidly identify potential etiologies in syndromic presentations (eg, CNS, GI, respiratory, bloodstream) and when faster turnaround or limited specimen volume is important.

LimitationsMay have variable sensitivity for certain pathogens and can produce false positives with low pretest probability; results require clinical correlation and, where applicable, adjunctive testing (eg, culture, serology).

inv-62: Blood culture

DefinitionBlood culture = Standard culture‑based method to detect bloodstream infections; serves as the reference standard for organism identification and susceptibility testing.

Adjunct testingMultiplex molecular blood culture identification panels (eg, BCID) or direct‑from‑blood assays can provide faster organism ID and resistance markers to complement blood culture, particularly after antibiotic administration.

LimitationsBlood culture sensitivity decreases after prior antibiotics and may miss fastidious/slow‑growing organisms; molecular assays may detect organisms earlier but are often limited to predefined target panels.

inv-63: 16S rRNA sequencing limitation

Limitation16S rRNA sequencing may not resolve differences beyond rRNA regions (eg, surface antigens or toxin genes) and can report some targets only at the genus level, limiting species or pathogenic strain differentiation.

ImplicationCertain clinically relevant distinctions (eg, pathogenic versus nonpathogenic strains) may not be made by 16S sequencing alone; complementary testing or clinical correlation may be needed.

Technical notePCR‑based and sequencing assays can introduce errors/artifacts during amplification that may affect detection accuracy.

inv-64: FilmArray Meningitis/Encephalitis (ME) panel

DefinitionFilmArray Meningitis/Encephalitis (ME) panel = FDA‑approved qualitative multiplex PCR panel for simultaneous detection of multiple bacterial, viral, and yeast nucleic acids from CSF specimens in symptomatic patients.

Key performance and specimen requirementThe BioFire FilmArray ME panel tests approximately 14 pathogens using 0.2 mL of CSF and provides results in ~1 hour; manufacturer‑reported sensitivity 94.2% and specificity 99.8%.

Clinical impactStudies report high percent positive agreement for bacteria and viruses and demonstrate reduction in antibiotic days and inpatient days when used appropriately.

inv-65: Multistep algorithm for C. difficile

DefinitionMultistep algorithm for C. difficile = Use of GDH plus toxin; GDH plus toxin arbitrated by NAAT; or NAAT plus toxin rather than NAAT alone to improve diagnostic accuracy.

Guideline recommendationIDSA/SHEA recommend multistep testing algorithms and advise against repeat testing within 7 days.

RationaleMultistep algorithms reduce the risk of misdiagnosing colonization as infection compared with NAAT‑only approaches.

inv-66: Multiplex nucleic acid tests

DefinitionMultiplex nucleic acid tests = Qualitative assays that simultaneously detect and identify multiple viral, bacterial, parasitic, or fungal nucleic acids from clinical specimens for symptomatic patients.

Intended useFDA‑cleared multiplex NAATs (respiratory, GI, CSF, blood culture panels) are intended for use in symptomatic patients with signs/symptoms of the corresponding infection.

ExamplesIncludes assays such as FilmArray ME (CSF), FilmArray GI (stool), Verigene RV+, and various respiratory/gastrointestinal multiplex panels cleared by FDA.

inv-67: Proprietary panel / test

DefinitionProprietary panel / test = A named laboratory's multiplex molecular assay listed alongside a CPT/PLA code that targets multiple organisms and/or resistance genes using PCR or NGS methods.

Examples and codesExamples include ePlex RP Panel (PLA 0115U), ePlex BCID panels (0140U, 0141U, 0142U), Karius® Test (0152U), and other PLA codes mapping proprietary assays to CPT/PLA descriptors.

Policy implicationSome proprietary tests are enumerated with CPT/PLA codes; payers may reference these codes for coverage and prior authorization decisions.

inv-68: Syndromic multiplex PCR panel

DefinitionSyndromic multiplex PCR panel = Commercially available assays that detect multiple respiratory, gastrointestinal, CNS, or bloodstream pathogens from a single specimen using multiplex PCR technology.

Clinical roleUsed to rapidly identify etiologies in syndromic presentations where results will impact management (eg, directing therapy, infection control, or inpatient care decisions).

Evidence and limitationsEvidence shows high sensitivity/specificity for many panels and potential reductions in antibiotic days and length of stay, but utility varies by syndrome and test; guideline recommendations temper routine outpatient use for large panels.